Applied Genetic Technologies (AGTC) – StreetInsider.com Reports
-
Applied Genetic Technologies (AGTC) Said Syncona Limited Extended Offer to Purchase All Shares at $0.34/Sh
-
Syncona Commences Tender Offer for Applied Genetic Technologies (AGTC)
-
Applied Genetic Technologies Corp. (AGTC) PT Lowered to $0.40 at Wells Fargo
-
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.34%
-
Chardan Capital Markets Downgrades Applied Genetic Technologies Corp. (AGTC) to Neutral
-
H.C. Wainwright Downgrades Applied Genetic Technologies Corp. (AGTC) to Neutral
-
Stifel Downgrades Applied Genetic Technologies Corp. (AGTC) to Hold
-
Wedbush Downgrades Applied Genetic Technologies Corp. (AGTC) to Neutral
-
Applied Genetic Technologies (AGTC) Acquired by Syncona for Up to $73.5M
-
Wells Fargo Downgrades Applied Genetic Technologies Corp. (AGTC) to Equal Weight
-
Applied Genetic Technologies Corp. (AGTC) PT Lowered to $16 at H.C. Wainwright
-
Applied Genetic Technologies Corp. (AGTC) PT Lowered to $3 at Stifel
-
BTIG Downgrades Applied Genetic Technologies Corp. (AGTC) to Neutral
-
AGTC (AGTC) Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
-
Applied Genetic Technologies (AGTC) Prices 16.67M Share Offering at $0.60/sh
-
Applied Genetic Technologies (AGTC) Announces Proposed Underwritten Public Offering
-
Applied Genetic Technologies Corp. (AGTC) PT Lowered to $10 at BTIG
-
Applied Genetic Technologies (AGTC) Reports Positive Three-Month Interim Results from Skyline Trial of AGTC-501
-
Applied Genetic Technologies (AGTC) Reports Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501
-
Stifel Reiterates Buy Rating, $10 Price Target on Applied Genetic Technologies (AGTC), Sees Potential for Significant Upside from SKYLINE Trial Readout
-
Pre-Open Stock Movers 03/22: (GEVO) (RAIL) (BABA) Higher; (STAB) (AGTC) (OKTA) Lower
-
Applied Genetic Technologies (AGTC) Prices 7.5M Share Offering at $1.31/sh
-
After-Hours Stock Movers 03/21: (HRT) (XAIR) (NKE) Higher; (STAB) (AGTC) (TME) Lower
-
Applied Genetic Technologies (AGTC) Announces Proposed Stock Offering, Size not Disclosed
-
Applied Genetic Technologies (AGTC) to Offer Common Stock
-
Stifel Reiterates Buy Rating on Applied Genetic Technologies Corp. (AGTC)
-
Applied Genetic Technologies Corp. (AGTC) PT Lowered to $10 at Stifel, Following Earnings
-
Applied Genetic Technologies (AGTC) Reports Q2 Loss of $0.45/sh
-
Applied Genetic Technologies (AGTC) Reiterated at Buy by Stifel, ACHMB3 Progress is Encouraging
-
Long-Term Data May Add Momentum Behind Applied Genetic's (AGTC) AGTC-501 - Stifel
-
Applied Genetic Technologies Corp. (AGTC) PT Lowered to $9 at Wedbush, Following Clinical Business Update
-
Applied Genetic Technologies (AGTC) Appoints James Robinson to its Board
-
Applied Genetic Technologies (AGTC) Appoints Abraham Scaria as Chief Science Officer
-
Applied Genetic Technologies (AGTC) Misses Q1 EPS by 5c; Reports Cash and Cash Equivalents of $90.5M
-
UPDATE: Applied Genetic Technologies (AGTC) PT Lowered to $12 at Stifel (CORRECTION)
-
Applied Genetic Technologies (AGTC) Tops Q4 EPS by $0.12
-
Applied Genetic Technologies (AGTC) Appoints Yehia Hashad to its Board
-
Applied Genetic Technologies (AGTC) Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene
-
Applied Genetic Technologies (AGTC) to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
-
BTIG Starts Applied Genetic Technologies Corp. (AGTC) at Buy
-
Applied Genetic Technologies (AGTC) Reports Q3 Loss of $0.40/sh
-
Otonomy (OTIC) and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
-
Applied Genetic Technologies (AGTC) Reports Process Development Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT
-
Applied Genetic Technologies (AGTC) Announces Positive 12-Month Data from Highest Dose Groups in Ongoing XLRP Phase 1/2 Clinical Trial
-
Stifel Reiterates Buy Rating on Applied Genetic Technologies Corp. (AGTC) After Safety Update on AGTC-501 at ARVO
-
Pre-Open Movers 04/27: (FCBP) (GMBL) (ALDX) Higher; (RNWK) (AGTC) (HYFM) Lower (more...)
-
After-Hours Stock Movers 04/26: (HSII) (GME) (VMW) Higher; (RNWK) (AGTC) (PQG) Lower (more...)
-
Applied Genetic Technologies (AGTC) licenses Promoter Technology to SparingVision SAS
-
Pre-Open Stock Movers 03/02: (INUV) (TMDX) (RKT) Higher; (FGEN) (LODE) (AI) Lower (more...)
-
After-Hours Stock Movers 03/01: (ZM) (PSN) (NLSN) Higher; (FGEN) (AI) (INSG) Lower (more...)
Back to AGTC Stock Lookup